Navigation Links
MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial
Date:10/29/2010

amine (DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines. Based on clinical results, the company believes that LEVADEX has the potential to provide both fast onset of action, sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy.

LEVADEX is designed to incorporate the multiple beneficial mechanisms of action that allow DHE to block initiation of migraine, limit pain, reduce inflammation and stop a migraine at any point in the migraine cycle. Based on research to date, including the efficacy portion of the FREEDOM-301 trial, the company believes the unique pharmacokinetic profile of LEVADEX has the potential to effectively treat migraines, while minimizing the side effects commonly seen with DHE and other currently available medicines.

About Migraine Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound). According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies. Migraine patients report that currently approved drugs do not fully meet their needs due to slow onset of action, short duration of effect, inconsistent response and unacceptable side effect profiles. The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

About MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The Company is developing LEVADEX inhaled therapy for the
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... October 17, 2014 Investor-Edge has ... (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ... research on these five companies can be accessed at: ... Thursday, October 16, 2014, ended on a mixed note ...
(Date:10/17/2014)... -- UBM Medica US announces that Endocrinology Network , ... who treat patients with type 2 diabetes ... insulin .  Nearly all patients with ... – daily injections of one or more insulin formulations—to ... of pancreatic beta cells. Insulin is a very effective ...
(Date:10/17/2014)...  China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... approval from the China Food and Drug Administration ... complex concentrate ("PCC") at its Shandong Taibang facility. ... production facility for Good Manufacturing Practices ("GMP") compliance ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... Laser,Centers, the largest provider of laser hair removal ... the addition of the VelaShape,cellulite reduction and body ... 30 additional locations before the end of March, ... FDA-approved for both cellulite,reduction and circumferential reduction of ...
... has,received its third $10 million tranche of equity funding ... milestones:,validating the efficacy and safety of its two topical ... influenza vaccine in,ferret studies., The company, a spin-off ... $30 million over the past 18 months from Perseus ...
Cached Medicine Technology:American Laser Center Offers VelaShape Body Shaping and Cellulite Reduction Treatment 2NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones 2
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
(Date:10/20/2014)... 20, 2014 Houston plastic surgeon ... key elements of his innovative True Form Tummy ... surgery residents and faculty at The University of ... too, was once a medical student. Patronella, who is ... cosmetic plastic surgery practices in Texas, The Aesthetic ...
(Date:10/19/2014)... UNITED NATIONS, New York (PRWEB) October 19, 2014 ... the United Nations Population Fund, welcomes news of a ... release of the more than 200 girls who were ... Girls. "These girls have languished in captivity long enough, ... their families, schools and communities," stated Dr. Osotimehin. , ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... who do not have osteoporosis , , FRIDAY, Jan. 18 ... downplay the risks of prescribing bone-strengthening drugs for women ... osteoporosis, a new report claims. , Drugs such as ... fractures of women with osteoporosis, according to the article ...
... funding promotes diabetes care improvement at a community-level, ... throughout the,U.S. in implementing and evaluating models for ... Business Coalition on Health,(NBCH) announced the recipients of ... for NBCH member coalitions -- intended to support ...
... JOSE, Calif., Jan. 18 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of venous reflux disease, today,announced ... and,Vice President of Finance and Administration., Mr. Osborne ... in,various senior leadership roles. Mr. Osborne had served as ...
... M.D., distinguished professor of microbiology and immunology and of ... of Yeshiva University, has received the second annual Marshall ... a special ceremony at the medical school. , ... long-time member of the Einstein faculty, Marshall S. Horwitz, ...
... Antipolis, France ---Bridging the unacceptable gap between what is ... the prevention of cardiovascular disease is how Prof Guy ... of the European Society of Cardiology (ESC), summarises the ... , Creating incentives for people to make healthy ...
... to detect surface cancers quickly and painlessly using ... composition has been developed by a QUT PhD ... School of Physical and Chemical Sciences has developed ... diagnose cervical and skin cancers. , Bioimpedance measures ...
Cached Medicine News:Health News:Bone-Strengthening Drugs May Be Overprescribed 2Health News:Bone-Strengthening Drugs May Be Overprescribed 3Health News:National Business Coalition on Health Awards Grants to 14 Coalitions for Diabetes Quality Programs 2Health News:National Business Coalition on Health Awards Grants to 14 Coalitions for Diabetes Quality Programs 3Health News:VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer 2Health News:Einstein honors Dr. Stanley Nathenson with Marshall S. Horwitz Faculty Prize for Research Excellence 2Health News:European Summit on Cardiovascular Disease Prevention 2
Woodlyn Lensmeter is designed to be used in either a prescription laboratory setting or professional office. Its titable position angle offers personal comfort. The easily operated marking device pro...
Nidek Fundus Camera NM-200D's compact, lightweight body with user-friendly color touch screen display provides more options to treat more patients, and is more comfortable to use....
... high resolution 1640 x 1280 digital ... - digital achieves new levels of ... use. Now supplied complete with Kowa's ... image and patient management software this ...
The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation....
Medicine Products: